Issues
-
Cover Image
Cover Image
Shining a light on cholangiocarcinoma. NanoString imaging highlights spatial interactions between tumor cells (green), T cells (red), and stromal cells (yellow) within the cholangiocarcinoma tumor microenvironment. The recruitment of immune cells, activation of stromal cells, and proliferation of epithelial cells is a feature of cholangiocarcinoma. Dysregulation of WNT and NOTCH signaling pathways is critical to proliferation and invasion and occurs through activation of the PRH transcription factor, which is thereby able to increase epithelial-mesenchymal plasticity and transit through the cell cycle. Image collected by Dr. Jingjing Gong (NanoString), Dr. Isioma Egbuniwe (histopathologist, University of Nottingham, United Kingdom), Professor K. Gaston (University of Nottingham), and Dr. P.S. Jayaraman (University of Birmingham, United Kingdom). For details, see article by Kitchen and colleagues on page 757. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Insights
Review
Cancer Research Highlights
Controversy and Consensus
Metabolism and Chemical Biology
Unshielding Multidrug Resistant Cancer through Selective Iron Depletion of P-Glycoprotein–Expressing Cells
A Feedback Circuitry between Polycomb Signaling and Fructose-1, 6-Bisphosphatase Enables Hepatic and Renal Tumorigenesis
Molecular Cell Biology
Tumor Biology and Immunology
A Runaway PRH/HHEX-Notch3–Positive Feedback Loop Drives Cholangiocarcinoma and Determines Response to CDK4/6 Inhibition
IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung
Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity
Translational Science
Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features
Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts
Convergence and Technologies
Resource Report
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.